Clinic Roundup

• Repros Therapeutics Inc., of The Woodlands, Texas, said the FDA advised the firm it must complete an integrated safety analysis of completed studies of oral Proellex and submit a report for review prior to any additional trials testing oral administration of telapristone acetate, Proellex's active ingredient.